Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease
This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic…
- Trial name
- NCT07633314
- Testing
- TQC3927 inhalation aerosol, Glyceryl bromide/formoterol inhalation aerosol
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD…
- Trial name
- NCT02719184
- Where
- 51 sites in United States, Belgium and 10 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the effect of aclidinium bromide compared with placebo in improving dilatation of the airways (bronchodilation), symptoms of chronic obstructive pulmonary disease (COPD), sleep quality and…
- Trial name
- NCT02153489
- Testing
- Aclidinium bromide
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
CHF6297 is a potent and selective inhibitor of human MAP kinase p38 being developed as an anti-inflammatory agent for the treatment of inflammatory airways diseases.
- Trial name
- CHF6297 FIH (NCT02815488)
- Testing
- CHF6297 (Part 1 - SAD), CHF6297 (Part 2 - MAD), CHF6297 (Part 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and…
- Trial name
- NCT01899742
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 64 sites in United States, Argentina and 8 more
- Volunteers
- 497 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy of Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium Bromide Administered Via Dry Powder Inhaler in COPD
- Trial name
- TRI-D (NCT03590379)
- Testing
- CHF 5993 DPI, CHF5993 pMDI, CHF 1535 pMDI
- Where
- Bulgaria
- Volunteers
- 366 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Sleep Apnea, Asthma
Sleepiz One+ vs. Capnography and Electrocardiography
Respiratory Rate (RR) and heart rate (HR) are vital signs crucial for assessing a patient's overall health, providing insights into various conditions and stressors.
- Conditions
- Sleep Apnea, Asthma, COPD, Hypertension
- Trial name
- NCT06569940
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.
- Trial name
- NCT01388920
- Testing
- Tesamorelin
- Volunteers
- 3 people
- Sponsor
- Theratechnologies
COPD
Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)
This retrospective observational study aims to report distribution of the proportion of symptomatic Chronic obstructive pulmonary disease (COPD) patients classified by the COPD Assessment Test (CAT) managed with single or dual…
- Trial name
- REMIND (NCT05903989)
- Where
- Japan
- Volunteers
- 708 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
Pulmonary Disease, Chronic Obstructive
Repeat Dose Study in Male Healthy Volunteer Smokers
This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers
- Trial name
- NCT00615576
- Testing
- SB-656933
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose
AZD5069 is a new drug being tested for the possible treatment of people with chronic obstructive pulmonary disease (COPD). This is not the first time that AZD5069 will be administered to humans in clinical trials.
- Trial name
- NCT01083238
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
Effect of CHF 6001 on biomarkers of inflammation in induced sputum and in blood, on pulmonary function and on symptoms benefits in comparison with placebo.
- Trial name
- NCT03004417
- Testing
- CHF 6001 Dose1, CHF 6001 Dose2
- Where
- United Kingdom
- Volunteers
- 61 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.
- Trial name
- NCT00782535
- Testing
- CHF 4226 pMDI
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the long -term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo in patients with COPD.
- Trial name
- COPD (NCT02172287)
- Testing
- Tiotropium (Ba679 BR), Salmeterol
- Volunteers
- 623 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT06547333
- Testing
- CM310
- Volunteers
- 884 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
This is a Post-hoc analysis based on the database of "A non-interventional, retrospective study on AECOPD treatment status in China".
- Trial name
- CONTAIN (NCT03633838)
- Where
- China
- Volunteers
- 5,067 people
- Sponsor
- AstraZeneca
COPD
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF…
- Trial name
- NCT01730404
- Testing
- CHF6001 DPI, Roflumilast
- Where
- 5 sites in Ireland, United Kingdom
- Volunteers
- 55 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Emphysema
Post Market Registry Study of the AeriSeal System
Obtain and analyze medical record data on patients with advanced emphysema who receive treatment with the AeriSeal System to better understand safety and effectiveness in the post-market setting; Provide participating physicians…
- Trial name
- NCT01520064
- Where
- 12 sites in Germany, Israel
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
COPD
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
This study will evaluate whether prompt initiation and maintenance of Breztri (a triple therapy) following a severe COPD exacerbation hospitalization, is associated with a lower risk of all-cause readmissions at 90 days…
- Trial name
- IKANOS (NCT05970263)
- Testing
- Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.